Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARION, IN · NPI 1871731935
Verified facts
CMS Open Payments records show Jeffrey S Fuller, NP received $13.65 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.65 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 664 | 36 |
| Furosemide | Furosemide | 613 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 445 | 33 |
| Lisinopril | Lisinopril | 401 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 22 |
| Gabapentin | Gabapentin | 374 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 289 | 13 |
| Eliquis | Apixaban | 271 | 17 |
| Famotidine | Famotidine | 267 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 223 | 45 |
| Potassium Chloride | Potassium Chloride | 193 | 16 |
| Donepezil Hcl | Donepezil Hcl | 183 | suppressed |
| Tradjenta | Linagliptin | 167 | suppressed |
| Metformin Hcl | Metformin Hcl | 166 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 164 | suppressed |
| Carvedilol | Carvedilol | 158 | 12 |
| Losartan Potassium | Losartan Potassium | 150 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 141 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 136 | suppressed |
| Finasteride | Finasteride | 127 | suppressed |
| Meloxicam | Meloxicam | 126 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 123 | suppressed |
| Levetiracetam | Levetiracetam | 122 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 109 | suppressed |
| Omeprazole | Omeprazole | 109 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 106 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 104 | 15 |
| Torsemide | Torsemide | 101 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | suppressed |
| Memantine Hcl | Memantine Hcl | 92 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | suppressed |
| Mirtazapine | Mirtazapine | 91 | suppressed |
| Phenobarbital | Phenobarbital | 90 | suppressed |
| Trulicity | Dulaglutide | 84 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 76 | 22 |
| Montelukast Sodium | Montelukast Sodium | 75 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 70 | 12 |
| Midodrine Hcl | Midodrine Hcl | 65 | suppressed |
| Jardiance | Empagliflozin | 62 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 61 | suppressed |
| Nystatin | Nystatin | 60 | 27 |
| Primidone | Primidone | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 57 | suppressed |
| Amoxicillin | Amoxicillin | 56 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 56 | 33 |
| Allopurinol | Allopurinol | 54 | suppressed |
| Gemtesa | Vibegron | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 53 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 52 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Prednisone | Prednisone | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 19 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 12 |
| Insulin Lispro | Insulin Lispro | 34 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 19 |
| Sucralfate | Sucralfate | 33 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Clonidine | Clonidine | 31 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 25 | suppressed |
| Pimozide | Pimozide | 25 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Lorazepam | Lorazepam | 23 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 14 |
| Loperamide | Loperamide Hcl | 19 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.65 · 1 records | ABBVIE INC. | DALVANCE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error